Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13580314 | 0.81 | POLB (0.58) | KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL19502480 | 0.76 | MTNR1A (0.42) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL3427007 | 0.71 | ALDH1A1 (0.52) | MTNR1AMTNR1BKDM4EMAPTALDH1A1 | |
| SCHEMBL17980619 | 0.70 | NPC1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL13580209 | 0.69 | OXTR (0.40) | MAPTALDH1A1HPGD | |
| SCHEMBL13580313 | 0.69 | OXTR (0.40) | MAPTALDH1A1HPGD | |
| SCHEMBL1120195 | 0.69 | MTNR1A (0.45) | MTNR1AMTNR1BMAPTALDH1A1 | |
| SCHEMBL1120196 | 0.69 | MTNR1A (0.45) | MTNR1AMTNR1BMAPTALDH1A1 | |
| SCHEMBL19502481 | 0.68 | MTNR1A (0.52) | MTNR1AMTNR1BHPGD | |
| SCHEMBL4322629 | 0.68 | GLA (0.77) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | MTNR1A 997/4885MTNR1B 358/4885KDM4E 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.